In a lab in Cape Town, scientists at Biovac are refining the final stages of a locally produced measles vaccine—one small step toward a future where African nations no longer wait in line for life-saving immunizations. For too long, the continent has relied on distant factories in Europe, Asia, and North America, where vaccines are developed and deployed long before they reach clinics in Lagos, Nairobi, or Lusaka. That imbalance sparked a movement. In 2024, African leaders and global health partners launched the Africa Vaccine Manufacturing Accelerator (AVMA), a bold initiative with a clear mission: produce more than 60% of Africa’s vaccines by 2040. Backed by $1.2 billion in funding over ten years, the program aims to transform a continent long dependent on imports into a self-reliant hub of vaccine innovation and production. With 1.6 billion people—20% of the world’s population—Africa currently manufactures only a tiny fraction of the vaccines it uses, leaving it vulnerable during global health crises like the COVID-19 pandemic, when wealthier nations secured early access while African countries waited.
The AVMA emerged from the Health and Prosperity Through Immunizations Summit, hosted by Gavi, the Vaccine Alliance, and now stands at a pivotal moment as it approaches its second anniversary. The Gavi board is set to meet in early July 2026 to consider additional financing and new strategies to strengthen regional vaccine markets. Success hinges not just on building factories, but on creating sustainable ecosystems—where governments commit to procuring locally made vaccines, regulators harmonize approval processes, and private sector leaders like Biovac’s Farrah Losper drive commercial viability. “Africa was at the back of the queue in terms of vaccines,” Losper said during a CSIS event, “whilst in the first world, people were sort of stockpiling and able to get vaccine stores.” That memory fuels the urgency.
Today, the Africa CDC, under leaders like Shanelle Hall and Folake Olayinka, is working hand-in-hand with national immunization programs to align manufacturing capacity with public health needs. David Kinder of Gavi emphasized the importance of development finance in bridging early-stage gaps, ensuring that promising projects don’t stall for lack of capital. The road ahead is complex—regulatory hurdles, supply chain logistics, and market confidence all remain challenges—but the momentum is real. If AVMA succeeds, it won’t just prevent future vaccine inequity; it will create jobs, strengthen health systems, and position Africa as a global player in pandemic preparedness. The vision is no longer a dream, but a plan in motion—one dose at a time.